June Verdict Expected For Gilead Sofosbuvir/Velpatasvir Combo
This article was originally published in Scrip
Gilead Sciences Inc. has won a priority review from the FDA for the firm's new drug application (NDA) for its once-daily fixed-dose combination of sofosbuvir (SOF), a nucleotide analogue NS5B polymerase inhibitor, which is marketed as a single agent under the brand name Sovaldi, and velpatasvir (VEL), an investigational pan-genotypic NS5A inhibitor, as a treatment for chronic hepatitis C virus (HCV).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.